Purchase this article with an account.
C.H. Lau, H.S. Kok, R.J. Cooling, P. McCluskey, H.M. A. Towler, S. Lightman; VITRECTOMY IN THE CONTROL OF REFRACTORY UVEITIC CYSTOID MACULAR OEDEM . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2679.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the efficacy of vitrectomy in the treatment of refractory uveitic cystoid macular oedema. Methods: A retrospective nonrandomized comparative interventional study. The 43 vitrectomized eyes (37 patients, mean age 39.4) had a mean pre–vitrectomy follow up of 36.1 months and 29.5 months post–vitrectomy. This group was compared to 68 non–vitrectomized eyes (40 consecutive non–infective uveitic patients, mean age 39.7) with a mean follow up period of 69.4 months. Results: At first visit the mean logMAR VA was significantly better (p<0.0005) in the nonvitrectomized eyes (0.37 ± 0.54) than vitrectomized eyes (0.64 ± 0.38). Although this difference was narrowed at last visit, the mean logMAR VA was still significantly better (p = 0.009) in the nonvitrectomized (0.42 ± 0.56) than vitrectomized eyes (0.57 ± 0.63). For non–vitrectomized eyes, there was no significant change to mean LogMAR VA from first visit to last visit. For vitrectomized eyes with CME, the mean logMAR VA reduced significantly (p = 0.033) from first visit to the time of vitrectomy (0.80 ± 0.46) but improved significantly (p = 0.005) after vitrectomy. In the non–vitrectomized eyes the mean logMAR VA reduced insignificantly (p = 0.49) from first to last visit. Conclusions: The visual outcome was favourable in vitrectomised eyes. Vitrectomy is useful in the management of refractory cystoid macular oedema not responding to medical treatment.
This PDF is available to Subscribers Only